{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:07:37Z","timestamp":1790766457970,"version":"4.1.0"},"reference-count":92,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018925","name":"Health Commission of Henan Province","doi-asserted-by":"publisher","award":["HNSWJW-2020028"],"award-info":[{"award-number":["HNSWJW-2020028"]}],"id":[{"id":"10.13039\/100018925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitor-associated inflammatory arthritis (ICI-IA) and polymyalgia rheumatica (PMR)-like syndromes are clinically important rheumatic immune-related adverse events, but definitions vary across studies. We estimated their occurrence in real-world cohorts and summarized clinical course and management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed, Ovid MEDLINE, Embase, Web of Science Core Collection, and Cochrane CENTRAL were searched from inception through July 25, 2026. Two reviewers independently screened studies, extracted data, and assessed risk of bias, with disagreements resolved by a third reviewer. Compatible single-group proportions were pooled using random-intercept binomial generalized linear mixed models; non-poolable clinical-course evidence was synthesized using the Synthesis Without Meta-analysis framework.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Sixty-five reports representing 63 studies were included. Five independent ICI-treated cohorts reported 140 study-defined\n                      <jats:italic>de novo<\/jats:italic>\n                      ICI-IA cases among 4,644 patients, yielding a pooled crude occurrence proportion of 2.87% (95% CI, 2.02%-4.07%; 95% prediction interval, 1.06%-7.53%; I\n                      <jats:sup>2<\/jats:sup>\n                      = 71.7%). Three of the five primary cohorts were at high risk of bias. Definitions varied; excluding the largest cohort, which used a broader clinician-suspected joint-symptom definition, yielded a pooled proportion of 2.61% (95% CI, 1.50%-4.79%). Three studies reported 19 PMR\/PMR-like events among 1,998 patients (1.08%; 95% CI, 0.32%-3.62%), with marked imprecision and heterogeneity. A 2026 cohort reporting 12 PMR cases among 734 patients was retained as contextual evidence because\n                      <jats:italic>de novo<\/jats:italic>\n                      timing could not be verified and possible overlap with an earlier report could not be excluded. Descriptive evidence showed heterogeneous phenotypes and disease courses, with persistence in some cohorts and remission in others. Glucocorticoids and disease-modifying antirheumatic drugs were frequently used, but comparative treatment effects could not be determined.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      In denominator-valid studies, approximately 3% of ICI-treated patients were classified as having\n                      <jats:italic>de novo<\/jats:italic>\n                      ICI-IA during variable study-specific follow-up. This is a crude study-period proportion, not a fixed-time incidence risk. Standardized definitions and prospective denominator-valid cohorts are needed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420261460334<\/jats:ext-link>\n                      , identifier CRD420261460334.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1959233","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:53:00Z","timestamp":1790765580000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Occurrence and clinical course of immune checkpoint inhibitor-associated inflammatory arthritis and polymyalgia rheumatica-like syndromes: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Chenyang","family":"Li","sequence":"first","affiliation":[{"name":"Fujian University of Traditional Chinese Medicine","place":["Fuzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruhui","family":"Fu","sequence":"additional","affiliation":[{"name":"Luoyang Orthopedic-Traumatological Hospital of Henan Province (Henan Provincial Orthopedic Hospital)","place":["Luoyang, China"]},{"name":"Henan University of Traditional Chinese Medicine","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxin","family":"Geng","sequence":"additional","affiliation":[{"name":"Fujian University of Traditional Chinese Medicine","place":["Fuzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunru","family":"Zhang","sequence":"additional","affiliation":[{"name":"Fujian University of Traditional Chinese Medicine","place":["Fuzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Yuan","sequence":"additional","affiliation":[{"name":"Luoyang Orthopedic-Traumatological Hospital of Henan Province (Henan Provincial Orthopedic Hospital)","place":["Luoyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peifeng","family":"Li","sequence":"additional","affiliation":[{"name":"Luoyang Orthopedic-Traumatological Hospital of Henan Province (Henan Provincial Orthopedic Hospital)","place":["Luoyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Fan","sequence":"additional","affiliation":[{"name":"Luoyang Orthopedic-Traumatological Hospital of Henan Province (Henan Provincial Orthopedic Hospital)","place":["Luoyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[{"name":"Luoyang Orthopedic-Traumatological Hospital of Henan Province (Henan Provincial Orthopedic Hospital)","place":["Luoyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"B5","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1136\/annrheumdis-2020-217139","article-title":"EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors","volume":"80","author":"Kostine","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00296-020-04665-7","article-title":"Immune checkpoint inhibitor-induced musculoskeletal manifestations","volume":"41","author":"Angelopoulou","year":"2021","journal-title":"Rheumatol Int"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1611692","article-title":"The clinical characteristics, mechanism and management of immune checkpoint inhibitor-related arthritis","volume":"16","author":"Gao","year":"2026","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1080\/1750743X.2024.2436838","article-title":"Musculoskeletal immune-related adverse events of PD-(L)1 inhibitors in melanoma: a systematic review and meta-analysis","volume":"16","author":"Roberts","year":"2024","journal-title":"Immunotherapy"},{"key":"B11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s41927-025-00528-5","article-title":"Immune checkpoint inhibitor associated vasculitis and polymyalgia rheumatica: a case series and systematic review","volume":"9","author":"Teel","year":"2025","journal-title":"BMC Rheumatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/medsci13020034","article-title":"Polymyalgia rheumatica (PMR) and polymyalgia rheumatica-like (PMR-like) manifestations in cancer patients following treatment with nivolumab and pembrolizumab: methodological blurred points identified through a systematic review of published case reports","volume":"13","author":"Manzo","year":"2025","journal-title":"Med Sci (Basel)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l6890","article-title":"Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline","volume":"368","author":"Campbell","year":"2020","journal-title":"BMJ"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200329","article-title":"2012 provisional classification criteria for polymyalgia rheumatica: a European league against rheumatism\/american college of rheumatology collaborative initiative","volume":"71","author":"Dasgupta","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"B16","volume-title":"JBI Manual for Evidence Synthesis","author":"Aromataris","year":"2020"},{"key":"B17","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13690-023-01215-y","article-title":"Methods for meta-analysis and meta-regression of binomial data: concepts and tutorial with stata command metapreg","volume":"82","author":"Nyaga","year":"2024","journal-title":"Arch Public Health"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/26.4.404","article-title":"The use of confidence or fiducial limits illustrated in the case of the binomial","volume":"26","author":"Clopper","year":"1934","journal-title":"Biometrika"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid Based Ment Health"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J Stat Softw"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae343","article-title":"Incidence of checkpoint inhibitor-associated inflammatory arthritis, immunomodulation and mortality in cancer patients on immunotherapy: a retrospective cohort study","volume":"64","author":"Bass","year":"2024","journal-title":"Rheumatology"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.90585","article-title":"Rheumatic immune-related adverse events: immune checkpoint inhibitor therapy and ramifications for health disparities","volume":"17","author":"Kobashigawa","year":"2025","journal-title":"Cureus"},{"key":"B23","article-title":"Checkpoint inhibitor inflammatory arthritis: single center case identification and chart validation [conference abstract","volume":"77","author":"Barasch","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/art.41949","article-title":"Predictors of rheumatic immune-related adverse events and de novo inflammatory arthritis after immune checkpoint inhibitor treatment for cancer","volume":"74","author":"Cunningham-Bussel","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000017348","article-title":"Immune-related adverse events in cancer patients treated with immune checkpoint inhibitors: A single-center experience","volume":"98","author":"Kaur","year":"2019","journal-title":"Med (Baltimore)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/po-25-00772","article-title":"Efficacy of immune checkpoint blockade in advanced upper tract urothelial cancer with DNA mismatch repair deficiency or microsatellite instability","volume":"10","author":"Moussa","year":"2026","journal-title":"JCO Precis Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.2024-0603","article-title":"Effect of age on rheumatic immune-related adverse events: experience from the canadian research group of rheumatology in immuno-oncology (CanRIO)","volume":"52","author":"Li","year":"2025","journal-title":"J Rheumatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2024.100775","article-title":"Durvalumab combined with pemetrexed-based chemotherapy in trial-ineligible patients with mesothelioma: a brief report","volume":"6","author":"Dagogo-Jack","year":"2025","journal-title":"JTO Clin Res Rep"},{"key":"B29","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.jgo.2018.02.011","article-title":"Nivolumab in routine practice for older patients with advanced or metastatic non-small cell lung cancer","volume":"9","author":"Sabatier","year":"2018","journal-title":"J Geriatr Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17152461","article-title":"Late-onset immune-related adverse events in patients with advanced melanoma: the LATENT study","volume":"17","author":"Pozas","year":"2025","journal-title":"Cancers"},{"key":"B31","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.mjafi.2023.07.007","article-title":"Real world experience on patterns of usage and toxicity profile of immunotherapy drugs in indian patients: a prospective observational study","volume":"81","author":"Kaushik","year":"2025","journal-title":"Med J Armed Forces India"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.14059","article-title":"Delayed immune-related adverse events in long-responders of immunotherapy: a single-center experience","volume":"20","author":"Kitano","year":"2024","journal-title":"Asia Pac J Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0274451","article-title":"Utility of periodic medical questionnaires and examinations for immune-related adverse event screening: A prospective observational study","volume":"17","author":"Azuma","year":"2022","journal-title":"PloS One"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2021-0250","article-title":"No association between BMI and immunotoxicity or clinical outcomes for immune checkpoint inhibitors","volume":"14","author":"Yeung","year":"2022","journal-title":"Immunotherapy"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1136\/annrheumdis-2022-eular.5360","article-title":"Ab1327 prevalence of immunorelated musculoskeletal adverse effects in patients with lung cancer or melanoma treated with immuno-checkpoint inhibitors","volume":"81","author":"Salvatierra Velasco","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-eular.252","article-title":"Op0278 musculoskeletal immune-related adverse events in 927 patients treated with immune checkpoint inhibitors for solid cancer","volume":"81","author":"Melia","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.13350","article-title":"Retrospective analysis of hospital admissions due to immune checkpoint inhibitor-induced immune-related adverse events (irAE)","volume":"17","author":"Ahern","year":"2021","journal-title":"Asia Pac J Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.cllc.2018.04.021","article-title":"Activity of nivolumab and utility of neutrophil-to-lymphocyte ratio as a predictive biomarker for advanced non\u2013small-cell lung cancer: a prospective observational study","volume":"20","author":"Fukui","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"B39","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ejca.2017.05.032","article-title":"Prevalence of immune-related systemic adverse events in patients treated with anti-programmed cell death 1\/anti-programmed cell death-ligand 1 agents: a single-centre pharmacovigilance database analysis","volume":"82","author":"Le Burel","year":"2017","journal-title":"Eur J Cancer"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.2025-0808","article-title":"Evaluating hip osteoarthritis as a risk factor for immune checkpoint inhibitor\u2013induced inflammatory arthritis","volume":"53","author":"Fitzpatrick","year":"2026","journal-title":"J Rheumatol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3390\/life13040877","article-title":"Rheumatic diseases development in patients treated by anti-PD1 immune checkpoint inhibitors: a single-centre descriptive study","volume":"13","author":"Ceccarelli","year":"2023","journal-title":"Life"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2023-eular.6181","article-title":"Ab1638 risk factors for developing rheumatic immune-related adverse events after immunotherapy with immune checkpoint inhibitors","volume":"82","author":"Liapi","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-eular.7386","article-title":"Thu0584 rheumatological immune-related adverse events associadted with immunotherapy in solid organ tumor. Study of 102 cases from a referral single center for last years","volume":"78","author":"Bilbao","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1391\u2013","DOI":"10.1136\/annrheumdis-2019-eular.5951","article-title":"Sat0594 adverse autoimmune events in cancer patientstreated with immunotherapy. Analysis of cases between 2011 and 2018","volume":"78","author":"Le\u00f3n","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3390\/medicina58010094","article-title":"Rheumatological adverse events following immunotherapy for cancer","volume":"58","author":"Cretu","year":"2022","journal-title":"Med (Kaunas)"},{"key":"B46","article-title":"Resolution of immune checkpoint inhibitors-induced inflammatory arthritis while maintaining active treatment with checkpoint inhibitors [conference abstract","volume":"75","author":"Ladouceur","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"B47","first-page":"2571","article-title":"Identification of biomarkers predicting steroid resistance in immune checkpoint inhibitor-induced arthritis [conference abstract","volume":"75","author":"Thimmapuram","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-eular.551","article-title":"Ab1426 predictors of rheumatic toxicities of immune checkpoint inhibitors and cancer outcomes in patients with advanced melanoma","volume":"81","author":"Bruce","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B49","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/1756-185x.13444","article-title":"Association of good oncological response to therapy with the development of rheumatic immune-related adverse events following PD-1 inhibitor therapy","volume":"22","author":"Liew","year":"2018","journal-title":"Int J Rheum Dis"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2022.105457","article-title":"Musculoskeletal immune-related adverse events in 927 patients treated with immune checkpoint inhibitors for solid cancer","volume":"90","author":"Melia","year":"2023","journal-title":"Joint Bone Spine"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-017-2069-9","article-title":"Characterization of arthralgia induced by PD-1 antibody treatment in patients with metastasized cutaneous malignancies","volume":"67","author":"Buder-Bakhaya","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212257","article-title":"Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer\u2014clinical aspects and relationship with tumour response: a single-centre prospective cohort study","volume":"77","author":"Kostine","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/art.40745","article-title":"Rheumatic syndromes associated with immune checkpoint inhibitors: a single-center cohort of sixty-one patients","volume":"71","author":"Richter","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1136\/annrheumdis-2023-eular.1788","article-title":"Ab1457 multidisciplinary prospective study of patients treated with immune checkpoint inhibitors who developed rheumatic immune-related adverse events","volume":"82","author":"L\u00f3pez Gonz\u00e1lez","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1331959","article-title":"Rapid identification of inflammatory arthritis and associated adverse events following immune checkpoint therapy: a machine learning approach","volume":"15","author":"Tran","year":"2024","journal-title":"Front Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez361","article-title":"An MRI study of immune checkpoint inhibitor\u2013induced musculoskeletal manifestations myofasciitis is the prominent imaging finding","volume":"59","author":"Daoussis","year":"2020","journal-title":"Rheumatology"},{"key":"B57","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.ard.2025.06.215","article-title":"Pos0859 polymyalgia-like syndrome in patients treated with checkpoint inhibitors: a faster prednisone tapering regimen as an effective treatment approach","volume":"84","author":"Llobell Uriel","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"B58","doi-asserted-by":"publisher","first-page":"13159","DOI":"10.1038\/s41598-026-43606-5","article-title":"Rheumatic immune-related adverse effects of immune checkpoint treatment: a retrospective multicentre study","volume":"16","author":"Llobell-Uriel","year":"2026","journal-title":"Sci Rep"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.02.024","article-title":"Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy","volume":"60","author":"Zimmer","year":"2016","journal-title":"Eur J Cancer"},{"key":"B60","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1002\/acr2.11181","article-title":"Higher checkpoint inhibitor arthritis disease activity may be associated with cancer progression: results from an observational registry","volume":"2","author":"Chan","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S1470-2045(22)00687-8","article-title":"Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAF V600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study","volume":"24","author":"Ascierto","year":"2023","journal-title":"Lancet Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01601","article-title":"Randomized phase III trial evaluating spartalizumab plus dabrafenib and trametinib for BRAF V600-mutant unresectable or metastatic melanoma","volume":"40","author":"Dummer","year":"2022","journal-title":"J Clin Oncol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00559-9","article-title":"Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial","volume":"23","author":"Long","year":"2022","journal-title":"Lancet Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.888377","article-title":"Clinical patterns and follow-up of inflammatory arthritis and other immune-related adverse events induced by checkpoint inhibitors. A multicenter study","volume":"9","author":"G\u00f3mez-Puerta","year":"2022","journal-title":"Front Med"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1111\/imj.16629","article-title":"Comparative study of management strategies for immune checkpoint inhibitor-induced inflammatory arthritis: rheumatologists versus oncologists","volume":"55","author":"Yoon","year":"2025","journal-title":"Intern Med J"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003795","article-title":"Immune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: a multicentre observational study","volume":"9","author":"Ladouceur","year":"2023","journal-title":"RMD Open"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007557","article-title":"Sex and anti-inflammatory treatment affect outcome of melanoma and non-small cell lung cancer patients with rheumatic immune-related adverse events","volume":"11","author":"Gente","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105516","article-title":"Neoadjuvant immunotherapy for nonmetastatic dMMR\/MSI colon cancer: a real-world retrospective AGEO study","volume":"10","author":"Lemaire","year":"2025","journal-title":"ESMO Open"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13488","article-title":"Immunotherapy as second-line treatment and beyond for non-small cell lung cancer in a single center of China: outcomes, toxicities, and clinical predictive factors from a real-world retrospective analysis","volume":"11","author":"Chen","year":"2020","journal-title":"Thorac Cancer"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0538","article-title":"Outcomes and toxicities of programmed death-1 (PD-1) inhibitors in hodgkin lymphoma patients in the United States: a real-world, multicenter retrospective analysis","volume":"24","author":"Bair","year":"2018","journal-title":"Oncologist"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/s2665-9913(25)00061-x","article-title":"Whole-body MRI in patients with arthralgia or inflammatory arthritis after exposure to immune checkpoint inhibitors: a single-centre prospective imaging study","volume":"7","author":"Harnden","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2025-005879","article-title":"Ultrasound-detected inflammation and structural changes in the joints, tendons and entheses of patients with cancer who developed arthritis or arthralgia after exposure to immune checkpoint inhibitors","volume":"11","author":"Di Matteo","year":"2025","journal-title":"RMD Open"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12081961","article-title":"Imaging findings in patients with immune checkpoint inhibitor-induced arthritis","volume":"12","author":"Ponce","year":"2022","journal-title":"Diagnostics"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010758","article-title":"Osteoarthritis increases the risk of inflammatory arthritis due to immune checkpoint inhibitors associated with tissue-resident memory T cells","volume":"13","author":"Paiola","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1002\/art.42406","article-title":"Early increase of circulating transitional B cells and autoantibodies to joint-related proteins in patients with metastatic melanoma developing checkpoint inhibitor\u2013induced inflammatory arthritis","volume":"75","author":"Gatto","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2023-eular.152","article-title":"Ab1499 two distinct subsets of immune checkpoint inhibitor-induced inflammatory arthritis defined by latent class analysis","volume":"82","author":"Cappelli","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2018.01.003","article-title":"Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors","volume":"17","author":"Lidar","year":"2018","journal-title":"Autoimmun Rev"},{"key":"B79","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1136\/annrheumdis-2016-209595","article-title":"Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab","volume":"76","author":"Cappelli","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23467","article-title":"Arthritis after cancer immunotherapy: symptom duration and treatment response","volume":"71","author":"Smith","year":"2018","journal-title":"Arthritis Care Res"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.70002","article-title":"Chronicity of immune checkpoint inhibitor\u2013associated inflammatory arthritis after immunotherapy discontinuation: results from the canadian research group of rheumatology in immuno-oncology database","volume":"7","author":"Ladouceur","year":"2025","journal-title":"ACR Open Rheumatol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.27145","article-title":"Extended follow-up of chronic immune-related adverse events following adjuvant anti\u2013PD-1 therapy for high-risk resected melanoma","volume":"6","author":"Goodman","year":"2023","journal-title":"JAMA Netw Open"},{"key":"B83","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1001\/jamaoncol.2021.0051","article-title":"Chronic immune-related adverse events following adjuvant anti\u2013PD-1 therapy for high-risk resected melanoma","volume":"7","author":"Patrinely","year":"2021","journal-title":"JAMA Oncol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2024.105795","article-title":"Resolution of immune checkpoint inhibitors-induced inflammatory arthritis while maintaining active treatment with checkpoint inhibitors and after its discontinuation: an observational study","volume":"92","author":"Ladouceur","year":"2025","journal-title":"Joint Bone Spine"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1136\/annrheumdis-2022-eular.3614","article-title":"Pos1356 treatment of immune checkpoint inhibitor-induced inflammatory arthritis and polymyalgia rheumatica","volume":"81","author":"Liapi","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/e49am5","article-title":"Clinical outcomes in cancer patients with immune checkpoint inhibitor-induced arthritis treated with methotrexate: a retrospective longitudinal monocentric pilot study","volume":"43","author":"Hysa","year":"2025","journal-title":"Clin Exp Rheumatol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-019-04451-2","article-title":"Hydroxychloroquine is a safe and effective steroid-sparing agent for immune checkpoint inhibitor\u2013induced inflammatory arthritis","volume":"38","author":"Roberts","year":"2019","journal-title":"Clin Rheumatol"},{"key":"B88","first-page":"2095","article-title":"Traditional disease modifying anti-rheumatic drugs, hydroxychloroquine, and\/or sulfasalazine are rapidly effective in immune checkpoint inhibitor-induced inflammatory arthritis [conference abstract","volume":"69","author":"Alperin","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.annonc.2024.08.2340","article-title":"Tocilizumab provides dual benefits in treating immune checkpoint inhibitor-associated arthritis and preventing relapse during ICI rechallenge: the TAPIR study","volume":"36","author":"Petit","year":"2025","journal-title":"Ann Oncol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1136\/annrheumdis-2017-eular.6532","article-title":"FRI0606 characteristics and treatment of new onset arthritis after checkpoint inhibitor therapy","volume":"76","author":"Christ","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000714","article-title":"Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy","volume":"4","author":"Leipe","year":"2018","journal-title":"RMD Open"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-014641","article-title":"Comparing immune-checkpoint inhibitor-mediated inflammatory arthritis to polymyalgia rheumatica: a prospective cohort study","volume":"14","author":"Tison","year":"2026","journal-title":"J Immunother Cancer"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1959233\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:53:02Z","timestamp":1790765582000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1959233\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":92,"alternative-id":["10.3389\/fimmu.2026.1959233"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1959233","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"article-number":"1959233"}}